Biotech Values

[acgood]

No, the fact that AMRN was asked to do an outcomes study means that they requested a path to FDA approval for an indication that requires CV outcomes data.

Nonetheless, as I published, I felt the odds of NCE were better than 50/50. Now not so sure. The decision certainly wasn't communicated to AMRN (or even made likely) long ago, or this meeting would have already occurred!